Medivation Receives Average Rating of “Hold” from Analysts (NASDAQ:MDVN)
Shares of Medivation (NASDAQ:MDVN) have received an average rating of “Hold” from the twenty-one brokerages that are currently covering the company, AnalystRatings.NET reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $97.00.
In other Medivation news, Insider Lynn Seely sold 20,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $89.42, for a total value of $1,788,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Medivation (NASDAQ:MDVN) opened at 91.26 on Tuesday. Medivation has a one year low of $48.15 and a one year high of $92.26. The stock has a 50-day moving average of $79.86 and a 200-day moving average of $72.55. The company has a market cap of $7.008 billion and a P/E ratio of 287.72.
Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was up 111.1% on a year-over-year basis. Analysts expect that Medivation will post $2.43 EPS for the current fiscal year.
A number of analysts have recently weighed in on MDVN shares. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note on Monday, August 25th. They now have a $89.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “positive” rating on shares of Medivation in a research note on Monday, August 18th. Finally, analysts at Aegis raised their price target on shares of Medivation from $125.00 to $130.00 in a research note on Friday, August 8th.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.